Compound ID | 1861
Synonym(s): MK0787 | N-Formimidoylthienamycin
Class: Beta-lactam (carbapenem)
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Binds to bacterial penicillin-binding proteins (PBP) and interferes with bacterial cell wall integrity and synthesis. Carbapenems bind to all PBPs, with PBP2 and PBP4 as the highest-affinity targets. Carbapenems have a very broad spectrum incl. non-fermenters and are not hydrolysed by most beta-lactamases with exception of carbapenemases |
| Description: | Semisynthetic, derived from thienamycin, combined with cilastatin to prevent degradation of imipenem by the renal enzyme dehydropeptidase 1. Combination of imipenem/cilastatin and relebactam |
| Institute where first reported: | MSAD Merck Co |
| Year first mentioned: | 1977 |
| Highest developmental phase: | Approved by FDA in 2019 |
| Development status: | Approved, off-patent |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/104838 |
| Guide to Pharmacology: | imipenem |
| Citations: |
|